89bio Inc

89bio — Technical Presentation (January 2022)

21 slides from 89bio's technical presentation, Jan 24, 2022

  1. Slide 1: Pegozafermin Phase 1b/2a NASH Histology Cohort Topline Results

    Exhibit 99.2 Pegozafermin (formerly BIO89-100) Phase 1b/2a NASH Histology Cohort Topline Results Nasdaq: ETNB January 24, 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in

  3. Slide 3: Growing Evidence of Strong Profile in NASH

    Pegozafermin – Growing Evidence of Strong Profile in Non-Alcoholic Steatohepatitis (NASH) Previously reported data from the phase 1b/2a study results showed: • Significant effect on liver and cardio-metabolic parameters • Low incidence of treatment-related adverse events (AEs) • Potential for every

  4. Slide 4: Phase 1b/2a NASH Trial Design – Randomized and Open-Label Cohorts

    Phase 1b/2a NASH Trial Design – Randomized and Open-Label Cohorts KEY INCLUSION CRITERIA C1-4 QW 3-27mg or (n=51) • Biopsy confirmed or phenotypic NASH placebo • PDFF≥10% C5-6 Q2W 18-36mg or (n=30) KEY ENDPOINTS placebo • Safety, PK C7 QW 27mg (n=20) • Relative changes in liver fat B B • Serum lipid

  5. Slide 5: Baseline Characteristics

    Baseline Characteristics Parameter Cohort 7 Cohorts 1-6 Mean or % (n=20) (n=81) Age (years) 58.4 51.9 Female 75.0% 61.7% Weight (kg) 104.6 93.6 2 BMI (kg/m ) 37.0 34.6 Type 2 Diabetes 85.0% 45.7% % F2 / % F3 35% / 65% NA NAS 5.3 NA MRI-PDFF (%) 21.1 21.3 ALT (U/L) 47.1 41.5 AST (U/L) 36.1 31.0 Pro-C

  6. Slide 6: Robustly Improved NAFLD Activity Score and All Components of NAS

    Pegozafermin Robustly Improved NAFLD Activity Score (NAS) and All Components of NAS ≥2pt Improvement in NAS Responder* Rates by NAS Component with ≥1pt Improvement in Ballooning or Inflammation • 63% of patients had ≥2point improvement in NAS and no 100% 100% worsening of fibrosis* 74% 79% 74% (prim

  7. Slide 7: Clinically Meaningful Changes on Key Histological Efficacy Endpoints

    Pegozafermin Demonstrated Clinically Meaningful Changes on Key Histological Efficacy Endpoints 75% NASH Resolution OR Improvement in Fibrosis ≥1 Stage NASH Resolution* 47% Improvement in Fibrosis** 32% 26% (95% CI: 13%-57%) (95% CI: 9%-51%) (6/19) (5/19) (9/19) 0% 100% of patients had ≥30% mean rela

  8. Slide 8: Substantially Improved Scores Across Non-Invasive Tests

    Pegozafermin Substantially Improved Scores Across Non-Invasive Tests (NITs) Correlated with Advanced Fibrosis Mean Relative Change From Baseline 0% -4.6 -0.47 -0.29 -4.3 NIT DESCRIPTIONS kPa ng/ml -10% • VCTE: FibroScan® liver stiffness -20% ** measure *** -19% -20% • FAST score: FibroScan (VCTE and

  9. Slide 9: High Percentages of Responders Based on Clinically Relevant NIT Thresholds

    Pegozafermin had High Percentages of Responders Based on Clinically Relevant Thresholds for NITs CLINICALLY RELEVANT THRESHOLDS 100% • VCTE: >20% reduction correlates 88% with fibrosis improvement 72% FAST score: Score ≤ 0.35 predicts • Fibrosis Stage F0/F1 and NAS <4 63% 58% • FIB-4 score: Score <1

  10. Slide 10: Robust Liver Fat Reduction with High Responder Rates

    Pegozafermin: Robust Liver Fat Reduction with High Responder Rates Consistent with Prior Cohorts Mean Relative Reduction in Liver Fat vs Baseline 20% 10% ≥30% Relative ≥50% Relative Reduction in Reduction in Placebo 0% Liver Fat Liver Fat Cohort 4 Cohort 6 Cohort 7 Cohort 7 100% 78% -20% Cohort 4 86

  11. Slide 11: Clinically Significant Reduction in ALT Consistent with Prior Cohorts

    Pegozafermin: Clinically Significant Reduction in ALT Consistent with Prior Cohorts ALT – Mean Change vs Baseline ALT – Absolute Change vs Baseline (U/L) (All Patients- Cohort 7) Patients with elevated ALT at baseline 0 20% Cohort 7 Cohorts 1-6 (n=14) (n=17) 0% -20% -46% *** *** *** *** -40% *** -27

  12. Slide 12: Improvement on HbA1c and Notable Body Weight Reduction

    Pegozafermin Demonstrated Clinically Meaningful Improvement on HbA1c and Notable Body Weight Reduction Weight Change Change in HbA1c (n=19) Patients with baseline Total patient population HbA1c ≥ 6.5% (n=10) (n=19) 0 0 0.0% *** -0.5% *** -3.9% -1 -1 ** -0.9% -5.0% HbA1c: Baseline: 7.3%; Week 20: 6.4

  13. Slide 13: Clinically Meaningful Improvements in Lipid Parameters

    Pegozafermin Demonstrated Clinically Meaningful Improvements in Lipid Parameters Percent Change in TG at Week 20 in Percent Change from Baseline at Week 20 Patients with Elevated TG at Baseline (n=11, mean=210 mg/dL) TG LDL-C non-HDL-C HDL-C 30% *** 0% 23% 0% *** -32% * -13% *** -18% -50% *** -30% -

  14. Slide 14: Improves Many Markers of Liver Health and Co-Morbidities Associated with NASH

    Pegozafermin Improves Many Markers of Liver Health and Co- Morbidities Associated with NASH INSULIN LIVER HEALTH OBESITY DYSLIPIDEMA RESISTANCE HbA1c HISTOLOGY NITs WEIGHT CHANGE^ TG^ Mean Absolute Reduction Cohort 7 Cohort 7 Cohort 7 88% Cohort 7 Cohort 4 Cohort 7 72% NAS >2 Cohort 7 Cohort 4 Cohor

  15. Slide 15: Well Tolerated Across Doses

    Pegozafermin Was Well Tolerated Across Doses Low Incidence of Treatment-Related AEs in ≥ 10% of Pooled Pegozafermin Group Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 Cohort 7 Pooled Preferred Term Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W 27mg QW pegoza n (%) (n=18) (n=7) (n=

  16. Slide 16: Next Step: Phase 2b (ENLIVEN) NASH Trial Design

    Next Step: Phase 2b (ENLIVEN) NASH Trial Design EXTENSION PHASE MAIN STUDY (24 weeks) (24 weeks) KEY INCLUSION CRITERIA • F2-F3 NASH; NAS ≥4 PLACEBO (QW or Q2W) PLACEBO* (QW or Q2W) PLACEBO Q2W PRIMARY ENDPOINTS Pegozafermin 15mg QW Pegozafermin 15mg QW • Fibrosis Improvement Pegozafermin 30mg QW Pe

  17. Slide 17: Cohort Results Confirm and Extend Evidence of Pegozafermin's Potential in NASH

    Cohort 7 Results Confirm and Extend the Growing Evidence of Pegozafermin’s Potential in NASH Robust effects across key histology endpoints Impressive results in non-invasive clinically relevant measures of overall liver health Significant changes in glycemic control, lipids and body weight address k

  18. Slide 18: Phase 1b/2a Results Provide Confidence in Severe Hypertriglyceridemia (SHTG)

    Phase 1b/2a Study Results Provide High Level of Confidence in Pegozafermin’s Benefits in Severe Hypertriglyceridemia (SHTG) KEY PARAMETERS OF INTEREST IN SHTG PEGOZAFERMIN RESULTS Triglyceride reduction (TG) (primary endpoint) LDL-c reduction Non-HDL-c reduction Liver fat reduction Glycemic control

  19. Slide 19: Rohit Loomba, MD, MHSc

    Rohit Loomba, MD, MHSc Director, NAFLD Research Center Professor of Medicine, Director of Hepatology University of California at San Diego 18

  20. Slide 20: Investment Highlights

    Investment Highlights Pegozafermin has potential to be a leading drug for liver and cardio-metabolic disorders • Validated with compelling profile: strong efficacy including histology in NASH, favorable safety/tolerability, and potential best-in-class dosing Pursuing two promising large indications

  21. Slide 21: Q&A

    Q&A

89bio — Technical Presentation (January 2022) on 6ix